



Disclaimer

This IR Presentation contains forward-looking statements that are based on management's expectations, estimates, projections and assumptions.

Actual results may differ from those we project and may be affected by the business environment, government regulation and legislation, financial market movement, or other factors.

All forward-looking statements speak only as of the date of this report. The company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

The Company has adopted its financial statements under International Financial Reporting Standards (IFRS) since 2011



Investor Relations

Contents

- I. Easy Bio Group
- II. Easy Bio
- III. Optipharm
- IV. Appendix



The background of the slide is an abstract composition of overlapping circles in various shades of green and yellow. Some of these circles contain images: one shows a lush green landscape with a winding path, and another shows a close-up of a plant with small white flowers. The overall aesthetic is clean and modern, with a focus on natural elements.


I Easy Bio Group

- 1. History**
- 2. Value chain**
- 3. Revenue & Operating Profit contribution**

1. History

Since EasyBio started biz as a feed additives & consulting co. in 1988, it has grown rapidly in agriculture & livestock industry


EasyBio Group's Consolidated Revenue Trend (million USD)



2. Value chain

EasyBio Group of 40 companies, as an agriculture/animal industry leader in Korea, doing Biz in 7 related industries

Value-chain of agriculture/animal industry




		1	2	3	4	5	6	7
Easy Bio Family		<ul style="list-style-type: none"> • Saedulman • Ecohoz 	<ul style="list-style-type: none"> • EasyBio 	<ul style="list-style-type: none"> • I-feed • Farmstory B&F • Seoul Feed • Easy Farms 	<ul style="list-style-type: none"> • Woorison • Farm's World 	<ul style="list-style-type: none"> • Farmstory LPC • Kangwon LPC 	<ul style="list-style-type: none"> • Maniker • DM • Sunghwa • Jayeonilg 	<ul style="list-style-type: none"> • Optipharm
Competitor	Domestic		<ul style="list-style-type: none"> • CJ cheiljedang 	<ul style="list-style-type: none"> • Nonghyup • Farmsco-Sunjin 			<ul style="list-style-type: none"> • Harim • Dongwoo 	
	Global	<ul style="list-style-type: none"> • Cargill • ADM 	<ul style="list-style-type: none"> • Bayer • DSM • AB Foods 	<ul style="list-style-type: none"> • CP • Cargill-Purina 		<ul style="list-style-type: none"> • Smith Field • Agrosuper 	<ul style="list-style-type: none"> • JBS • Tyson food 	

3. Revenue & Operating Profit contribution


The portion of sales revenue and operating profit occupies 8% and 23%

Revenue(1H, 2014)



Total Revenue : 725 Million USD

Operating Profit(1H, 2014)



Total O.P : 51 Million USD




II. Easy Bio

- 1. Company Overview**
- 2. Milestones**
- 3. Product Mix**
- 4. Business Matrix**
- 5. Domestic & Export Sales**
- 6. Export Sales by Region**
- 7. Sales Outlook(1)**
- 8. Sales Outlook(2)**
- 9. Market Trend of Global Feed Additive**
- 10. Product Portfolio**
- 11. Sales Outlook of Key Products**
- 12. Sales Organization**
- 13. Technical Competitiveness**
- 14. Phased Growth**

1. Company Overview


Company Name	EASY BIO, Inc.
CEO	JI WEON CHEOL
Establishment / Listing	Mar. 1988 / Nov. 1999 (KOSDAQ)
Outstanding Shares	50,524 Thousand Shares
Subsidiaries	40 Companies
Production Facilities	Cheonan City, Chungnam Province, Korea (2 sites with total 101,400 MT/year production capacity)
Web site	www.easybio.co.kr
Products	<p>Feed Additives : Products with specific functionality (Enzyme, Absorption enhancer, Prebiotics, Probiotics)</p> <p>Feed Supplements : Conventional and nutritional supplements in animal feed (Vitamin, Trace mineral, Organic acids, Concentrated fiber etc.)</p> <p>Milk replacement : Formula for young animals to replace milk</p>

2. Milestones



3. Product Mix

The continuous business shifts from milk replacement to feed additives




Total sales : 114 Million USD

Total sales : 125 Million USD

4. Business Matrix


“Feed Additives” as new growth engine and future cash-cow from current “Milk Replacement”



5. Domestic & Export Sales


Further global expansion through increasing the export sales

2013



Total sales : 114 Million USD


2014(E)



Total sales : 125 Million USD


6. Export Sales by Region

The Continuous diversification of partner distributors and sales countries




7. Sales Outlook(1)

Annual sales expected to reach USD 409 million by 2025;
with dramatic growth of overseas sales representing 27% annual growth




8. Sales Outlook(2)

Annual sales expected to reach USD 409million by 2025;
with dramatic growth of feed additives sales representing 20% annual growth



9. Market Trend of Global Feed Additives

Market trend change From "Animal Performance" to "Food safety and Sustainability"



Growing concern about " **Food safety through no medicine**" and " **Security of industrial sustainability through energy cost saving**"

10. Product Portfolio

Product family to meet the market trend of cost savings and food safety



The Digestion Accelerator

The optimal Multi-Enzymes producing by non-GMO microorganisms and solid state fermentation for corn-soybean meal based diet



The Absorption Accelerator

The improvement of cell membrane penetrability and the activation of protein channel for the nutrient absorption




The Metabolism Accelerator

- The promotion of absorbed nutrients utilization as a precursor of heme protein
- Antibiotics alternatives of new concepts


11. Sales Outlook of Key Products

The quantum jump by "Right market & Right products"




12. Sales Organization

Organizational evolution for strength of competitiveness in global market



13. Technical Competitiveness

Product families to meet the market trend of cost savings and food safety



- **Prevention of water pollution (Eco-friendly fermentation)**
- **Product with whole fermentation media and metabolites (vitamins, organic acids, UGF etc.)**
- **Naturally selected non-GMO microbial fermentation**
 - Various functional materials with side-effects as well as target materials
 - Biological asset and technical barrier against competitors

14. Phased Growth

Realization of the one of the leading companies in feed additives area by M&A and organic growth

Operation of overseas business with ~30 distributors and three subsidiaries in Canana, Russia and Philippines

Short-term (2015~2017)

Total 153 Mln. USD
(Overseas 37 Mln. USD)

- Two JV establishment in China & Latin America
- M&A of premix plant in South-eastern Asia
- Ten branch or liaison office establishment

Middle-term (2018~2021)

Total 232 Mln. USD
(Overseas 97 Mln. USD)

- Feed additives company M&A in Europe
- Production plant establishment in India
- Ten branch or liaison office establishment including Africa

Long-term (2022~2025)

Total 409 Mln. USD
(Overseas 251 Mln. USD)


- Overseas company M&A in enzyme, fermentation, coating business area
- Ten branch or liaison office establishment

The background of the slide is an abstract composition of overlapping circles in shades of blue, green, and purple. A prominent circle in the lower-left quadrant contains a detailed landscape scene with a winding path, trees, and a body of water. Other circles of varying sizes and opacities are scattered across the slide, creating a sense of depth and movement.


III. Optipharm

1. Business Scope
2. Xenotransplantation Plan
3. Bio-artificial liver Project
4. Opti-care(Bacteriophage)
5. Past, Present , Future of Optipharm


1. Business scope



2. Xenotransplantation Plan



3. Bio-artificial liver Project



Life-liver/Samsung medical center


2013.03.26 clinical test success (1/6 case)

2013.03.20 clinical test success (2/6 case)


2014.10.11 clinical test success (3/6 case)

4. Opti-care(Bacteriophage)

Monthly Sales



Sales outlook



5. Past, Present, Future of Optipharm

Past

2006 Establishment

2008 Merge with Medi-pig Korea

Present

2009 Leader or Diagnosis of animal
SPF Mini-pig

2010 Artificial organ project start
(Samsung medical center)

2013 Transformed pigs production

2014 Merge with M&D
(Human diagnosis kit)

Diagnostic kits for animal
Bacteriophage

2014 Sales
10Million USD Surplus

Future

2015 Bacteriophage expansion

2015 Artificial organ Project
comercialization

2016 Diagnostic kits for Human

2020 Xenotransplantation

(*) Xenotransplantation :
Successful engraftment of organs
from animals into humans


The background of the slide is an abstract composition of overlapping circles in various shades of blue, green, and purple. Some of these circles contain images: one shows a lush green landscape with a winding path and trees, while another shows a close-up of a mechanical or industrial component. The overall effect is a sense of depth and complexity.

IV. Appendix

- 1. Corporate structure**
- 2. Summary of Financial Statements**

1. Corporate Structure

[Sep. 2014]



2. Summary of Financial Statements(Consolidated)

(Million USD, Exchange Rate 1 USD = 1,000 KRW)

	Group			
Financial Statemetns	2011	2012	2013	2014.1H
INCOME STATEMENTS				
Sales	1,070	1,545	1,504	725
Gross profit	155	190	201	135
Operating profit	47	27	39	51
EBITDA	73	52	68	67
BALANCE SHEET				
Total assets	1,082	1,473	1,474	1,541
Total liabilities	824	1,131	1,113	1,148
Total equity	258	342	361	393